PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33599853-3 2021 In this study, we aimed to investigate the cytotoxic and anti-proliferative effects of bexarotene in C6 glioma cells through the PPARgamma/NF-kappaB pathway. Bexarotene 87-97 peroxisome proliferator activated receptor gamma Homo sapiens 129-138 33599853-7 2021 We found that bexarotene treatment decreased NF-kappaB and TAS levels and increased PPARgamma and 8-OHdG levels in C6 cells. Bexarotene 14-24 peroxisome proliferator activated receptor gamma Homo sapiens 84-93 33599853-8 2021 Bexarotene enhanced PPARgamma expression in a dose-dependent manner when compared to the control group (P < 0.01). Bexarotene 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 20-29 33599853-10 2021 In conclusion, bexarotene treatment in C6 glioma cells could modulate apoptosis profile, DNA damage, ROS production, and reduction of TAS levels through inhibition of NF-kappaB by enhancing PPARgamma expression. Bexarotene 15-25 peroxisome proliferator activated receptor gamma Homo sapiens 190-199 29642873-0 2018 Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway. Bexarotene 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 82-91 29642873-12 2018 CONCLUSION: These results suggest that bexarotene inhibits the viability of lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway. Bexarotene 39-49 peroxisome proliferator activated receptor gamma Homo sapiens 106-115 26451138-0 2015 Identification of Bexarotene as a PPARgamma Antagonist with HDX. Bexarotene 18-28 peroxisome proliferator activated receptor gamma Homo sapiens 34-43 26451138-3 2015 Here we have applied hydrogen/deuterium exchange (HDX) mass spectrometry to characterize the effects of Bexarotene on the conformational plasticity of the intact RXRalpha:PPARgamma heterodimer. Bexarotene 104-114 peroxisome proliferator activated receptor gamma Homo sapiens 171-180 26451138-4 2015 Interestingly, addition of Bexarotene to PPARgamma in the absence of RXRalpha induced protection from solvent exchange, suggesting direct receptor binding. Bexarotene 27-37 peroxisome proliferator activated receptor gamma Homo sapiens 41-50 26451138-6 2015 Furthermore, Bexarotene functioned as a PPARgamma antagonist able to alter rosiglitazone induced transactivation in a cell based promoter:reporter transactivation assay. Bexarotene 13-23 peroxisome proliferator activated receptor gamma Homo sapiens 40-49 22053058-6 2012 Bexarotene also induced mRNA and protein levels for peroxisome proliferator-activated receptor (PPAR) gamma, whereas selective knockdown of PPARgamma attenuated the induction of both lipid droplets and adipocyte differentiation-related protein. Bexarotene 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 52-107 22053058-10 2012 It is noteworthy that combining low doses of bexarotene with the PPARgamma agonist rosiglitazone provides effective growth suppression of mammary epithelial cells, potentially dissociating systemic adverse effects associated with standard bexarotene treatment from the antiproliferative effects on mammary epithelium. Bexarotene 239-249 peroxisome proliferator activated receptor gamma Homo sapiens 65-74 16495926-8 2006 The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma. Bexarotene 15-25 peroxisome proliferator activated receptor gamma Homo sapiens 127-175 34931381-7 2022 Combination treatment with pioglitazone and bexarotene increases PPARgamma DNA binding activity and IVL promoter activity (p < 0.01 and p < 0.0001). Bexarotene 44-54 peroxisome proliferator activated receptor gamma Homo sapiens 65-74 34931381-11 2022 CONCLUSIONS: Targeting the PPARgamma/RXRalpha heterodimer with pioglitazone and bexarotene was effective in this preclinical project. Bexarotene 80-90 peroxisome proliferator activated receptor gamma Homo sapiens 27-36 34142331-5 2021 Mechanistically, bexarotene promoted the nuclear translocation of RXR-alpha and PPAR-gamma, as well as reducing neuroinflammation by modulating microglia/macrophage reprograming from the M1 into the M2 phenotype. Bexarotene 17-27 peroxisome proliferator activated receptor gamma Homo sapiens 80-90 33599853-0 2021 Bexarotene inhibits cell proliferation by inducing oxidative stress, DNA damage and apoptosis via PPARgamma/ NF-kappaB signaling pathway in C6 glioma cells. Bexarotene 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 98-107 22223330-4 2012 Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists. Bexarotene 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 27-36 22223330-4 2012 Bexarotene alone activated PPARgamma/RXR and RXR/LXR heterodimers, but not RXR/VDR heterodimers, and facilitated the activation of all three RXR heterodimers by the respective PPARgamma, LXR, and VDR agonists. Bexarotene 0-10 peroxisome proliferator activated receptor gamma Homo sapiens 176-185 16729120-1 2006 Heterodimeric compounds based on tethering the PPARgamma agonist Rosiglitazone to the RXR ligand Targretin have been prepared. Bexarotene 97-106 peroxisome proliferator activated receptor gamma Homo sapiens 47-56